The Oral Rheumatoid Arthritis Trial (ORAL) Surveillance, a landmark post-marketing safety study, revealed an association between tofacitinib and a higher risk of MACE compared to anti-TNF-α agents in patients with RA aged ≥50 years with cardiovascular risk factors, thereby raising concerns [29]. This evidence concerns the gene TNF and rheumatoid arthritis.